Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
Completed
National Cancer Institute (NCI)
Phase 2
2000-08-01
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be
effective in preventing multiple myeloma.
PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone
with that of clarithromycin in treating patients who may be at a high risk of developing
multiple myeloma.
Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
Completed
Mayo Clinic
Phase 2
2000-08-01
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be
effective in preventing multiple myeloma.
PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone
with that of clarithromycin in treating patients who may be at a high risk of developing
multiple myeloma.
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
Completed
Celgene Corporation
Phase 2
2004-12-01
PRIMARY STUDY OBJECTIVES
- To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide
(Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with
newly diagnosed multiple myeloma (MM).
- To evaluate the safety of the combination of clarithromycin, lenalidomide, and
dexamethasone as an induction therapy for patients with newly diagnosed MM.
SECONDARY STUDY OBJECTIVES
- To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone
and lenalidomide.
- To examine the angiogenesis profile in untreated patients and in patients receiving
induction therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
